[Acceptability, tolerance and quality of life impact of cyproterone acetate treatment in female hirsutism. Comparison of 2 protocols in combination with oral or transdermal estradiol].
67 women (aged 16-40) with hirsutism and/or other signs of hyperandrogenism (acne, androgenic alopecia, cycle disturbances) have been treated for one year with cyproterone acetate + estradiol. Patients have been randomly assigned to therapy with cyproterone acetate and estradiol valerate per or cyproterone acetate and transdermal estradiol. Acceptance, tolerance and effects on quality of life of this treatment have been assessed using a self questionnaire completed with questions for assessment for compliance. Among patients who have had a full course of treatment, 54 have fulfilled the end-of-study quality of life questionnaire. The queries allow calculation of a relational well-being score and of an emotional well-being score. The answers to the initial questionnaire show in a high percentage of patients emotional trouble (depressive state, anxiety, irritability) and disturbances in relational life. The hirsutism score has been found to be significantly correlated with anxious trouble but not with the global quality of life score. The treatment has resulted in a significant improvement in acceptance of being exposed to view (p < 0.01), self-assurance (p < 0.01) as well as emotional well-being score (p < 0.05), without any significant difference between the 2 therapeutics groups. Measurement of treatment acceptance with a visual analogic scale has been found globally very satisfactory by patients from the 2 groups. Compliance of treatment with transdermal estradiol turned out to be lesser in younger patients but is better in patients in whom emotional balance has been improved by therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
Consoli
S M
SM
Unité médico-psychologique, Hôpital Broussais, Paris.
Vexiau
P
P
Consoli
S G
SG
Abramovici
Y
Y
D000279:Administration, Cutaneous; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D017373:Cyproterone Acetate / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006628:Hirsutism / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D010349:Patient Compliance; D011788:Quality of Life; D012720:Severity of Illness Index; D016896:Treatment Outcome
D017373:Cyproterone Acetate; D004958:Estradiol
Acceptabilité, tolérance et impact sur la qualité de la vie du traitement de la femme hirsute par l'acétate de cyprotérone. Comparaison de 2 schémas l'associant soit à l'estradiol per os, soit par voie transdermique.